Dupilumab in the Treatment of Pediatric Alopecia Areata
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study
will take place at four sites. This trial will enroll a total of 76 children and adolescent
subjects with moderate to severe AA (affecting more than 50% of the scalp) at the time of
screening with a targeted 60 subjects completing through Week 48. All subjects must have
evidence of hair regrowth within the last 7 years of their last episode of hair loss; and
have screening IgE ≥200 and/or have personal and/or familial history of atopy.
Study participation will be up to 116 weeks, consisting of: a screening period of up to 4
weeks; a 48-week placebo-controlled period; a 48-week open-label extension period; followed
by a 16-week follow-up period.